John Didsbury

John Didsbury has been in the pharmaceutical industry for over 25 years. John started their career at GlaxoSmithKline in 1995 as Head of Strategy and Operations for the Drug Discovery Center for Excellence in Drug Discovery (CEDD). In this role, they were responsible for the strategic direction and business plan for the center, as well as for business development and alliance management. John also chaired the Metabolic Diseases and Musculoskeletal Diseases Therapeutic Strategy Teams (TSTs) at GlaxoWellcome.

In 2002, John left GlaxoSmithKline to join T3D Therapeutics as President, CEO, and Chairman. T3D is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of diabetes, obesity, and other metabolic diseases. Under John's leadership, T3D has raised over $100 million in financing and advanced two of its lead drug candidates into Phase 2 clinical trials.

John Didsbury earned their B.A. in Biology and Chemistry from the University of Connecticut and their Ph.D. in Medical Microbiology from The Robert Larner, M.D. College of Medicine at The University of Vermont.

Some individuals on their team include Blake Swearingen - Director, Clinical Development, Warren Strittmatter - Chief Medical Officer, and Hoda Gabriel - VP, Clinical Development.